Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling
Guanyu Wang, Elizabeth Lakota, Bo Feng, Licong Jiang, Guiqing Liang, Brian Hare · 2026
Read Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling by Guanyu Wang, Elizabeth Lakota, Bo Feng, Licong Jiang, Guiqing Liang, Brian Hare (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13589259.txt.
Description
Guanyu Wang and five co-workers wrote a 2026 modeling study on whether a new pain drug interacts with two common blood thinners. The pain drug is a first-of-its-kind non-opioid pill for strong short-term pain. Early trials showed it mildly speeds a liver enzyme that breaks down other drugs. Both thinners are cleared partly by that enzyme.
Body-based computer models were checked against real trial data first. The models then forecast tiny drops in thinner exposure, under ten percent. That sits well inside the usual no-effect margin. The result matches the thinners' labels, which give no warning here. The team concludes no meaningful interaction is expected.
Catalog record
| CREATOR | Guanyu Wang, Elizabeth Lakota, Bo Feng, Licong Jiang, Guiqing Liang, Brian Hare |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |